LeMaitre Vascular, Inc. (LMAT) Formed a Wedge Up Pattern, Could Be One of The Best Performers Soon

September 16, 2018 - By Mary Markley

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Logo

Investors sentiment increased to 2.41 in Q2 2018. Its up 0.99, from 1.42 in 2018Q1. It improved, as 11 investors sold LeMaitre Vascular, Inc. shares while 28 reduced holdings. 32 funds opened positions while 62 raised stakes. 14.96 million shares or 9.18% more from 13.70 million shares in 2018Q1 were reported.
Amer Grp holds 0% or 12,078 shares. Louisiana State Employees Retirement Sys holds 0.01% of its portfolio in LeMaitre Vascular, Inc. (NASDAQ:LMAT) for 6,800 shares. Albion Fincl Gp Ut has invested 0.04% in LeMaitre Vascular, Inc. (NASDAQ:LMAT). Prelude Capital Mgmt Limited Liability, a New York-based fund reported 100 shares. Legal & General Public Ltd Co holds 0% of its portfolio in LeMaitre Vascular, Inc. (NASDAQ:LMAT) for 30,425 shares. Price T Rowe Assoc Md owns 0% invested in LeMaitre Vascular, Inc. (NASDAQ:LMAT) for 15,588 shares. Credit Suisse Ag holds 0% in LeMaitre Vascular, Inc. (NASDAQ:LMAT) or 22,900 shares. Pennsylvania-based Pnc Gp Inc has invested 0% in LeMaitre Vascular, Inc. (NASDAQ:LMAT). Wells Fargo Mn reported 145,124 shares or 0% of all its holdings. Envestnet Asset Management Inc holds 0% in LeMaitre Vascular, Inc. (NASDAQ:LMAT) or 6,121 shares. Bahl & Gaynor Incorporated holds 0.05% or 138,202 shares in its portfolio. Cadence Cap Management Limited Company holds 0.14% or 69,513 shares. Epoch Investment, a New York-based fund reported 932,093 shares. Colonial Tru Advsr reported 14,407 shares or 0.1% of all its holdings. State Board Of Administration Of Florida Retirement System holds 0% or 8,244 shares.

Since May 7, 2018, it had 0 buys, and 10 sales for $6.57 million activity. Shares for $533,369 were sold by LeMaitre George W. Jasinski Lawrence J had sold 1,000 shares worth $34,000 on Monday, May 7. On Thursday, August 23 the insider Pellegrino Joseph P JR sold $18,552.

The stock of LeMaitre Vascular, Inc. (LMAT) formed an up wedge with $37.81 target or 9.00 % above today’s $34.69 share price. The 9 months wedge indicates low risk for the $675.14 million company. If the $37.81 price target is reached, the company will be worth $60.76M more.
Rising wedges, especially for downward breakouts are tricky moments to trade. Investors must be aware that the break even failure rate for up or down breakouts is: 8% and 24%. The average rise is 28% and the decline is 14%. Wedges has high throwback and pullback rate: 73%, 63% and the percent of wedges meeting target is not more than 50%.

The stock decreased 0.26% or $0.09 during the last trading session, reaching $34.69. About 93,473 shares traded. LeMaitre Vascular, Inc. (NASDAQ:LMAT) has declined 9.94% since September 16, 2017 and is downtrending. It has underperformed by 25.56% the S&P500.

Analysts await LeMaitre Vascular, Inc. (NASDAQ:LMAT) to report earnings on October, 25. They expect $0.21 EPS, down 16.00 % or $0.04 from last year’s $0.25 per share. LMAT’s profit will be $4.09 million for 41.30 P/E if the $0.21 EPS becomes a reality. After $0.43 actual EPS reported by LeMaitre Vascular, Inc. for the previous quarter, Wall Street now forecasts -51.16 % negative EPS growth.

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Ratings Coverage

Among 4 analysts covering LeMaitre Vascular (NASDAQ:LMAT), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. LeMaitre Vascular had 4 analyst reports since April 26, 2018 according to SRatingsIntel. The company was upgraded on Thursday, April 26 by Benchmark. The company was downgraded on Thursday, April 26 by Stifel Nicolaus. Canaccord Genuity maintained the shares of LMAT in report on Monday, July 9 with “Hold” rating.

Another recent and important LeMaitre Vascular, Inc. (NASDAQ:LMAT) news was published by Globenewswire.com which published an article titled: “LeMaitre Vascular to Present at Upcoming Investor Conferences” on September 07, 2018.

LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company has market cap of $675.14 million. The firm offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature. It has a 32.12 P/E ratio. It also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; powered phlebectomy devices to remove varicose veins; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin.

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.